Alvotech SA - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALVO Nasdaq 8731 https://www.alvotech.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alvotech SA

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) - Apr 24th, 2024 8:00 am
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) - Apr 19th, 2024 10:10 am
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) - Apr 16th, 2024 9:43 pm
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 - Apr 3rd, 2024 11:41 am
Alvotech Announces Increase in Number of Own Shares - Mar 22nd, 2024 8:15 pm
Analysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before Long - Mar 22nd, 2024 1:37 pm
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update - Mar 20th, 2024 8:15 pm
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET - Mar 5th, 2024 9:01 pm
Alvotech Appoints Interim Chief Quality Officer - Feb 29th, 2024 9:05 pm
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share - Feb 26th, 2024 9:25 am
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® - Feb 24th, 2024 1:15 am
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) - Feb 15th, 2024 11:30 am
Is Alvotech (NASDAQ:ALVO) Trading At A 48% Discount? - Feb 4th, 2024 1:38 pm
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® - Jan 29th, 2024 9:00 am
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 - Jan 19th, 2024 4:30 pm
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Jan 10th, 2024 8:30 am
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) - Jan 3rd, 2024 8:30 am
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® - Nov 29th, 2023 9:00 am
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update - Nov 28th, 2023 9:15 pm
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET - Nov 21st, 2023 1:00 pm